Trials / Completed
CompletedNCT00105287
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Multi-center Study Evaluating OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OraVescent fentanyl (OVF) |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2006-09-01
- Completion
- 2007-09-01
- First posted
- 2005-03-14
- Last updated
- 2014-05-09
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00105287. Inclusion in this directory is not an endorsement.